Introduction: Early detection of lung cancer (LC) has been well established as a significant key point in patient survival and prognosis. New highly sensitive nanoarray sensors for exhaled volatile organic compounds that have been developed and coupled with powerful statistical programs may be used when diseases such as LC are suspected. Detection of genetic aberration mutation by nanoarray sensors is the next target.
Introduction
Lung cancer (LC) is the leading cause of cancerrelated death for both men and women worldwide. 1 Unfortunately, only 15% of new LC cases are being diagnosed at a localized stage. 2 The National Lung Screening Trial (NLST) demonstrated that LC screening by low-dose computed tomography scans reduced LC mortality rates by 20%, but among abnormal results, 96% were false-positive. 3 Lung nodules detected by computed tomography may lead to invasive procedures, whereas patients with pulmonary nodules may assume that they have cancer and suffer fear of death and fear of chemotherapy toxicity. 4, 5 The need to distinguish between benign and malignant pulmonary nodules calls for the development of diagnostic tools such as biomarkers (ideally, noninvasive tools). Exhaled volatile organic compounds (VOCs) are organic compounds that have a high vapor pressure at room temperature. They are generated either by various cellular biochemical processes in the body or by absorption from the environment through ingestion, inhalation, or skin contact. 6 Some of the VOCs may be involved or produced in biochemical processes such as oxidative stress or in cytochrome P-450, carbohydrate, or lipid metabolism. [7] [8] [9] Organic compounds with low solubility in the blood generally diffuse through gas exchange occurring in the lung alveoli, whereas the more soluble ones have a higher chance of diffusing throughout the bronchial tree. 10, 11 Breath samples might contain up to 3000 different VOCs, mostly at low concentrations (parts per trillion to parts per billion). 12 Using a colorimetric sensor array, Mazzone et al. demonstrated a sensitivity of 73.3% and specificity of 72.4% in distinguishing patients with NSCLC from those with other pulmonary diseases and control participants. 13 Recently, by using mass spectrometry, Schumer et al. found that four volatile carbonyl compounds could be sensitive markers for LC, with specificity proportional to the number of the elevated markers.
14 Nanoarray sensors allow the identification of a large number of VOCs through precise monitoring of changes in electrical resistance. When pattern recognition methods and classification techniques are used, the combined response from all sensors establishes a volatolomic signature. Diseases such as cancer lead to a shift in the composition of these organic compounds, presenting a unique breath print in exhaled air. 10, 11, 15 In recent years, a growing body of evidence has shown that patients with cancer can be distinguished from other patients or healthy individuals by a unique VOC pattern that is identified by a combination of very sensitive chemical nanoarray sensors and powerful computerized analysis learning models. 13, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In a study of 14 patients with bronchogenic carcinoma and 45 controls without cancer, nanoarray sensors had a sensitivity of 71.4% and a specificity of 91.9% for detecting LC. 20 In another study, specific breath prints of patients with NSCLC could be distinguished from those of patients with chronic obstructive pulmonary disease and healthy controls. 19 Also, nanoarray sensors successfully distinguished between patients with head and neck cancer, patients with LC, and healthy controls. 23 A recent cross-sectional study that included use of a chemiresistor-based alkane sensor demonstrated that the peak output and the time to peak values for patients with LC were statistically different from those for chronic obstructive pulmonary disease and healthy controls. 26 LC was diagnosed with sensitivity of 83.3% and a specificity of 88%. In another interesting study performed by Peralbo-Molina et al., five different metabolites (monopalmitin, benzyl alcohol, monostearin, 2,4-diphenyl-4-methyl-2-E-pentene, and p-cresol) were used to form three panels. 27 Patients with LC were differentiated from healthy controls and patients with risk factors with a sensitivity higher than 77.9%, a specificity higher than 67.5% and an area under the curve higher than 77.5%.
The next challenge is to discriminate histologically between different types of cancers in the same organ or between different stages of cancer. In our previous study we used gold nanoparticle (GNP) sensors to distinguish VOCs from cell lines of healthy individuals and different types of LCs. 24 We could discriminate significantly between lung carcinoma and healthy cells, between NSCLC and SCLC cells, and between adenocarcinoma and squamous cell carcinoma (SCC) with 9% to 96% accuracy. In another study by our group we evaluated patients with pulmonary nodules from the University of Colorado Cancer Center (Aurora, CO) and Denver Veterans Affairs Medical Center (Denver, CO). 25 The nanoarray sensors distinguished successfully between benign and malignant nodules, between adenocarcinomas and SCCs, and between early-stage and advanced disease with an accuracy of 88%.
A more interesting aspiration in cancer detection is to identify genetic aberrations that could alter treatments. In our previous pilot study of cell lines we identified the volatile fingerprints that are associated with EGFR and KRAS mutations as well as with echinoderm microtubule protein associated like 4 (EML4)-ALK receptor tyrosine kinase gene (ALK) rearrangements. 28 Unique fingerprints of KRAS and tumor protein p53 gene (TP53) were also found in bronchial epithelial cell lines by Davis et al. 29 Furthermore, in a clinical study using ion mobility spectrometry, Handa et al. were able to discriminate patients with LC with or without EGFR mutation. 30 In this study we aimed to evaluate the potential of exhaled breath analysis in the diagnosis of the EGFR mutation in patients with LC. On the basis of our previous studies with patients with cancer, we selected a unique set of 40 sensors. We explored the system in discriminating patients with LC who harbor the EGFR mutation from those with wild-type EGFR and also reexamined the system's ability to distinguish early LC from benign pulmonary nodules. Furthermore, we used our system to identify different breath prints between patients with LC and a history of heavy recent smoking and never-smokers or distant past light smokers.
Methods
The study was conducted at the Sheba Medical Center (SMC), Israel, which is a tertiary medical center. Patients with suspicious lung lesions referred for evaluation at our Institute of Pulmonology were recruited for the study. Patients were classified as having benign pulmonary nodule according to histological subtype or if their nodules were radiographically stable throughout at least 2 years of follow-up. Patients with LC were classified as having early (stage I and II) or advanced (stage III and IV) disease. Breath samples from patients with LC were collected before any treatment. Ethical approval was obtained from the ethics committee of SMC for supervision of human experiments (8663-11-SMC), and the clinical trial was registered at ClinicalTrials.gov (NCT01386203). All patients were provided with a written and verbal explanation about the study before their enrollment, and they signed a written consent of participation.
Breath Collection
Breath samples for patients scheduled for biopsy were collected before the procedures. To minimize the effect of confounding factors on the analysis, the volunteers were asked to not ingest coffee and food for at least 1 hour or alcohol for at least 12 hours and to avoid smoking for at least half an hour before the breath collection. Lung washout to reduce exogenous VOCs was performed by 3 minutes of inhalation through a mouthpiece with a filter cartridge on the inspiratory port mouthpiece (Eco Medics, Duerten, Switzerland). The patients were asked to inhale to the level of total lung capacity and then to slowly exhale through the mouthpiece against 10 to 15 cm H 2 O pressure to ensure closure of the vellum so as to eliminate contamination through nasal entrainment. To focus on the VOCs originating in the blood, we collected alveolar air. The respiratory dead space air was collected by using a designated 440-mL bag that was then removed while the remaining alveolar air from the lungs was collected in 750-mL GaSampler collection bags (QuinTron, Milwaukee, WI). Two bags were collected per patient. The air samples were trapped and preconcentrated by pumping the contents of the bag through a sorbent tube for 7 minutes (flow rate 100 mL/min) in two-bed ORBOTM 420 reusable Tenax TA sorbent tubes for gas and vapor sampling (specially treated, 35/60 mesh, 100/50 mg [Sigma-Aldrich, St. Louis, MO]). The Tenax tubes were stored and transported at 4 C to the Laboratory for Nanomaterial-Based Devices at Technion-Israel Institute of Technology in Haifa, Israel. Because we used different Tenax tubes with different absorption capacity, this group was analyzed separately from the patients from our previous studies.
Nanoarray Sensors
The nanomaterial-based sensor array used in this study contained 40 cross-reactive, chemically diverse chemiresistors based on two types of nanomaterials: (1) organically stabilized spherical GNPs (core diameter 3-4 nm) and (2) single-walled carbon nanotubes (SWCNTs) capped with polycyclic aromatic hydrocarbon (PAH) or hexabenzocoronene (HBC). Previous articles have described synthesis of the GNPs 17, 18, 31, 32 and SWCNTs. 32 The GNP and SWCNT/PAH or SWCNT/HBC sensors used in this study responded rapidly and reversibly when exposed to typical breath VOCs. On the basis of our previous research, we chose 40 sensors (26 GNP, eight SWCNT/PAH, and six SWCNT/HBC sensors) that were able to distinguish between patients with cancer and subjects without cancer.
The fabricated sensors were mounted on a custom polytetrafluoroethylene circuit board inside a stainless steel test chamber with a volume of 330 mL that delivers pulses of the breath samples from the thermal desorption device to the chemical nanoarray. The samples underwent thermal desorption (at 250 C) in an autosampler thermal desorption system (TD20 [Shimadzu Corporation, Japan]), and the desorbed samples were temporarily stored in a stainless steel column (at 150 C). In parallel, the chamber containing the sensors was kept under vacuum conditions (w30 mTorr) until the sample was directed into the chamber, and the remaining volume was filled with N 2 (99.999%) until atmospheric pressure was reached. A model 2701 DMM Keithley data logger device (Tektronix, Beaverton, OR) was used to obtain sequential resistance readings from the sensor array during 5 minutes in a vacuum before exposure (baseline), followed by 5 minutes of breath sample filling the chamber and then followed by another 5 minutes of sensor recovery starting with chamber vacuum. The whole system was controlled by a custom-made Lab-VIEW program, and the chamber was evacuated between exposures. An Agilent multifunction switch 34980 (Agilent Technologies, Waldbronn, Germany) was used to measure the resistance of all sensors as a function of time. To supervise the sensor's functionality during the experiment and also to overcome its response drift, a fixed calibration gas mixture containing 23.8 ppm isopropyl alcohol, 6.3 ppm trimethylbenzene, and 1.2 ppm 2-ethylhexanol was exposed to the sensors on a daily basis, and the raw signals of response of the breath samples were normalized by its parallel response to the calibration gas measured the same day. The samples were run blindly and then analyzed at the TechnionIsrael Institute of Techology.
Statistical Analysis
From each sensor response to a breath sample, four sensing features were read out: the normalized change of the sensor's resistance at the peak, middle, and end of the exposure and the area under the curve (resistance over time). Discriminate function analysis (DFA) was used to classify the data. 17 DFA performs a multivariate test of differences between groups and is used to determine the minimum number of dimensions needed to describe these differences. A distinction is sometimes made between descriptive discriminant analysis and predictive discriminant analysis. DFA derives canonical variables (CVs) (linear combinations of the interval variables) that summarize between-class sensors in much the same way that principal components summarize total variation. Given two or more groups of observations with measurements on several interval variables, DFA derives the linear combination of the variables that has the highest possible multiple correlation with the groups. This maximal multiple correlation is called the first canonical correlation. The coefficients of the linear combination are the canonical coefficients or canonical weights. The variable defined by the linear combination is the first canonical correlation or canonical component. The second canonical correlation is obtained by finding the linear combination uncorrelated with the first CV that has the highest possible multiple correlation with the groups. The process of extracting CVs can be repeated until the number of CVs equals the number of original variables or the number of classes minus one, whichever is smaller.
To prevent overfitting of the data, we used the minimal number of sensing features to build a discriminative model, stressing a ratio of features to samples lower than 1:6. The leave-one-out cross-validation method was then used to calculate the accuracy of prediction. The Wilcoxon test was used to identify the statistically significant prediction models. Statistical analysis was carried out using SAS JMP, version 10.0 (SAS Institute, Inc., Cary, NC). We used Kruskal-Wallis one-way analysis of variance and parametric chi-square tests with SPSS Statistics for analysis of the clinical characteristics.
Results
Between January 2012 and May 2014, a total of 119 patients were enrolled in the study. Benign nodules were identified in 30 patients, and LC was diagnosed in 89 patients, with early LC diagnosed in 16 patients and advanced LC diagnosed in 73. Clinical characteristics are summarized in Table 1 . As expected, patients with benign pulmonary nodules were younger, smoked less, and had smaller nodules than patients with LC. Of the 30 patients with benign (or likely benign) nodules, three had granulomatous nodules, one had an inflammatory nodule, three had nodules that were nonspecific on biopsy, and 23 did not have a biopsy. Of the 89 patients with confirmed LC, 73 had adenocarcinoma, nine had SCC, and seven had SCLC (all extensive disease). Table 2 summarizes the performance of the exhaled breath analysis with nanoarray technology for the different groups. Good performance was obtained for discriminating early LC from benign nodules, with an accuracy of 87% by two sensor sets (Fig. 1) , with each set comprising a different combination of sensors and/or sensing features. The use of two different sets of sensors provides additional validation for the results. For this comparison, we found a relatively low sensitivity (75%) and a high specificity (93%), with a positive predictive value (PPV) and negative predictive value (NPV) of 87.7% and 87.5%, respectively.
A subgroup of the patients with LC included 19 patients in whom the EGFR mutation was diagnosed and 34 patients with LC who did not harbor any EGFR mutation. The clinical characteristics of this subgroup are shown in Table 3 . As expected, smoking was significantly lower in the EGFR mutation-positive group. When five different sensors were used, the nanoarray sensors discriminated between patients with LC with EGFR mutation-positive tumors and those with EGFR mutation-negative tumors. Patients harboring EGFR mutation were discriminated from those with wild-type EGFR with an accuracy of 83%, sensitivity of 79%, specificity of 85%, PPV of 75%, and NPV of 88% (see Table 2 and Fig. 2 ).
We were interested to see whether the LC of patients with a history of heavy smoking could be differentiated from the LC of never-smokers or distant past light smokers by volatolomic signature. We used the smoking criteria of the National Lung Screening Trial study to classify our patients. 3 Of the 89 patients with LC, 50 met the criteria of current smokers or those who had quit smoking during the past 15 years and with a smoking history of at least 30 pack-years (PYs). We found 26 patients who had never smoked or quit smoking more than 15 years before the study with a smoking history of less than 30 PYs. We analyzed the differences between these two extreme groups and excluded 13 patients from the smoking analysis: active smokers with a smoking history of less than 30 PYs, those who had quit smoking during the past 15 years with a smoking history of less than 30 PYs, and those who had quit smoking more than 15 years ago with a smoking history of at least 30 PYs. Breath analysis could discriminate between the heavier smokers and the lighter smokers with an accuracy of 76.3%, and a sensitivity and specificity of 78% and 73%, respectively (see Table 2 ).
Discussion
By using highly sensitive nanoarray sensors and DFA as a powerful statistical tool, we established the concept that different diseases have different breath prints. The primary aim of this study was to discriminate patients with LC who harbor EGFR mutation from those with wild-type EGFR by breath print analysis using nanoarray sensors. Our system was able to identify a unique breath print in patients with LC with the EGFR mutation with an accuracy of 83%. We used a unique set of 40 sensors, which led to high accuracy in detecting the EGFR mutation in a clinical setting.
We also compared LC with benign nodules, with results similar to those from previous studies. 13, 14, 19, 20, 26, 27 In our previous pilot study of patients from Colorado, we showed that benign pulmonary nodules could be well discriminated from LC by a unique breath print. 25 The nanoarray sensors could also discriminate between adenocarcinomas and SCCs and between early-stage and advanced disease. The current study demonstrated that patients with early LC could be discriminated from patients with benign pulmonary nodules with a sensitivity, specificity, and accuracy of 75%, 93%, and 87% respectively. Both PPV and NPV were high (approximately 88%), indicating the efficiency and suitability of the test. However, because of the small number of patients with early LC (n ¼ 16), these results should be interpreted carefully.
To the best of our knowledge, this is the first clinical study of VOCs that discriminates a mutation of LC in humans by breath print. Previously, we were able to detect mutations in in vitro settings. 28 Further studies are needed to support this observation. Because we had a small number of patients with SCCs and SCLC, we could not analyze histological differences; however, this technology has shown such discrimination in vitro. 24 We suggest that in cases with a negative result of histological testing for EGFR mutation and in which tissue sampling does not provide adequate material for sequencing, a positive breath print for the EGFR mutation could be considered a true positive EGFR result for adenocarcinoma.
The third major (and second novel) finding in this study is the difference in breath prints between LC of nonsmokers or distant past light smokers and that of heavy smokers (active or recent quitters). In previous studies, 16, 33, 34 we have found that the sensor array output is not affected by current smoking. Tan et al. 26 have made a similar finding. To the best of our knowledge, this is the first publication of breath print analysis that distinguishes between LC in heavy smokers from that in light-to-minimal smokers, suggesting a possible metabolic difference between LCs in these two groups.
There are several limitations to this study. Most important is the small study population and, in particular, the small number of cases of early LC and EGFR mutation. Second, the classification as benign nodules in most cases was determined by 2 years of radiographically stability instead of by tissue diagnosis. Another limitation is that the analysis regarding smoking history is, as expected, subject to recall bias. We expect that further larger studies with larger populations would provide more accurate results.
These encouraging findings support the field of VOCs as a marker for LC using breath print analysis. There is potential in the future to identify breath prints by sensors through a portable, inexpensive device that is easy to use and provides rapid results. This may become the method of choice in the field of VOC analysis.
